PDF(Pubmed)
Abstract：
BACKGROUND: Evaluating the risk of relapse is a pivotal step in the treatment of patients with methamphetamine use disorder (MUD). The 30-item Stimulant Relapse Risk Scale (SRRS) was originally developed in Japan to meet the demand. This study examined the reliability, validity, and factor structure of the Chinese version of the SRRS for patients with MUD.
METHODS: 247 patients with MUD self-rated the Chinese version of the SRRS. Cronbach\'s alpha coefficients and inter-item correlation analysis were used to assess the internal consistency reliability. Construct validity was determined through confirmatory factor analysis (CFA), and concurrent validity was examined using the visual analogue scale (VAS) for drug craving and the severity of dependence scale (SDS). We followed the participants for 1 year and assessed the predictive validity based on the correlation of the scores of the Chinese version of the SRRS with the relapse rate within 3, 6, and 12 months of follow-up.
RESULTS: CFA revealed satisfactory model fit estimates for the 22-item Chinese version of the SRRS that consisted of four subscales. The four-factored 22-item Chinese version of the SRRS had adequate internal consistency with Cronbach\'s alphas ranging from 0.76 to 0.92. The 22-item Chinese version of the SRRS scores were significantly correlated with the VAS and SDS scores as well as the relapse rate within 3, 6, and 12 months, indicating good concurrent and predictive validity of this scale. The receiver operating characteristic curve revealed a cutoff score of 40 could discriminate between participants with (SDS score ≥ 4) and without (SDS score < 4) methamphetamine dependence (area under the curve = 0.71, p < 0.01).
CONCLUSIONS: The 22-item Chinese version of the SRRS that consists of four subscales is a valid and reliable instrument to assess the relapse risk in patients with MUD.
METHODS: 247 patients with MUD self-rated the Chinese version of the SRRS. Cronbach\'s alpha coefficients and inter-item correlation analysis were used to assess the internal consistency reliability. Construct validity was determined through confirmatory factor analysis (CFA), and concurrent validity was examined using the visual analogue scale (VAS) for drug craving and the severity of dependence scale (SDS). We followed the participants for 1 year and assessed the predictive validity based on the correlation of the scores of the Chinese version of the SRRS with the relapse rate within 3, 6, and 12 months of follow-up.
RESULTS: CFA revealed satisfactory model fit estimates for the 22-item Chinese version of the SRRS that consisted of four subscales. The four-factored 22-item Chinese version of the SRRS had adequate internal consistency with Cronbach\'s alphas ranging from 0.76 to 0.92. The 22-item Chinese version of the SRRS scores were significantly correlated with the VAS and SDS scores as well as the relapse rate within 3, 6, and 12 months, indicating good concurrent and predictive validity of this scale. The receiver operating characteristic curve revealed a cutoff score of 40 could discriminate between participants with (SDS score ≥ 4) and without (SDS score < 4) methamphetamine dependence (area under the curve = 0.71, p < 0.01).
CONCLUSIONS: The 22-item Chinese version of the SRRS that consists of four subscales is a valid and reliable instrument to assess the relapse risk in patients with MUD.
摘要：
背景：评估复发风险是治疗甲基苯丙胺使用障碍（MUD）患者的关键步骤。30项兴奋剂复发风险量表（SRRS）最初是在日本开发的，以满足需求。这项研究检查了可靠性，有效性，MUD患者SRRS的中文版和因子结构。
方法：247例MUD患者自评估中文版SRRS。使用Cronbachα系数和项目间相关性分析来评估内部一致性可靠性。通过验证性因子分析(CFA)确定结构效度，并使用视觉模拟量表（VAS）检查药物渴望和依赖程度量表（SDS）的同时有效性。我们对参与者进行了1年的随访，并根据SRRS中文版评分与随访3、6和12个月内复发率的相关性评估了预测有效性。
结果：CFA揭示了由四个分量表组成的22项中文版SRRS的令人满意的模型拟合估计。SRRS的四因素22项中文版与Cronbach的阿尔法在0.76至0.92之间具有足够的内部一致性。22项中文版的SRRS评分与VAS和SDS评分以及3、6和12个月内的复发率显着相关。表明该量表具有良好的并发和预测效度。受试者工作特征曲线显示，截止分数为40可以区分具有（SDS评分≥4）和没有（SDS评分<4）甲基苯丙胺依赖性的参与者（曲线下面积=0.71，p<0.01）。
结论：由四个分量表组成的22项中文版SRRS是评估MUD患者复发风险的有效且可靠的工具。
方法：247例MUD患者自评估中文版SRRS。使用Cronbachα系数和项目间相关性分析来评估内部一致性可靠性。通过验证性因子分析(CFA)确定结构效度，并使用视觉模拟量表（VAS）检查药物渴望和依赖程度量表（SDS）的同时有效性。我们对参与者进行了1年的随访，并根据SRRS中文版评分与随访3、6和12个月内复发率的相关性评估了预测有效性。
结果：CFA揭示了由四个分量表组成的22项中文版SRRS的令人满意的模型拟合估计。SRRS的四因素22项中文版与Cronbach的阿尔法在0.76至0.92之间具有足够的内部一致性。22项中文版的SRRS评分与VAS和SDS评分以及3、6和12个月内的复发率显着相关。表明该量表具有良好的并发和预测效度。受试者工作特征曲线显示，截止分数为40可以区分具有（SDS评分≥4）和没有（SDS评分<4）甲基苯丙胺依赖性的参与者（曲线下面积=0.71，p<0.01）。
结论：由四个分量表组成的22项中文版SRRS是评估MUD患者复发风险的有效且可靠的工具。
